The estimated Net Worth of Thomas C Reynolds is at least $2.52 Миллион dollars as of 19 December 2019. Thomas Reynolds owns over 10,000 units of Seagen Inc stock worth over $2,288,600 and over the last 18 years Thomas sold SGEN stock worth over $228,692.
Thomas has made over 18 trades of the Seagen Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Thomas bought 10,000 units of SGEN stock worth $16,000 on 19 December 2019.
The largest trade Thomas's ever made was exercising 125,079 units of Seagen Inc stock on 15 January 2013 worth over $1,453,418. On average, Thomas trades about 14,331 units every 75 days since 2007. As of 19 December 2019 Thomas still owns at least 10,000 units of Seagen Inc stock.
You can see the complete history of Thomas Reynolds stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro... и Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: